6 -12 (74) 2024 - G.U. Ashirbekova, U.U. Jabborov - INDICATORS OF INNATE CELL IMMUNITY IN HEMOLYTIC DISEASE OF THE FETAL IN PREGNANT WOMEN WITH Rh-IMMUNIZATION.

INDICATORS OF INNATE CELL IMMUNITY IN HEMOLYTIC DISEASE OF THE FETAL IN PREGNANT WOMEN WITH Rh-IMMUNIZATION.

G.U. Ashirbekova - Republican Perinatal Center, Uzbekistan

U.U. Jabborov - Republican Perinatal Center, Uzbekistan

Kh.M. Khatamov - Republican Perinatal Center, Uzbekistan

Resume

This study investigates changes in cellular immunity in fetuses with hemolytic disease in the context of Rh sensitization during pregnancy. Significant decreases in CD3+ and CD4+ T-helper cells and increases in CD8+ and CD16+ cytotoxic lymphocytes were observed in the II and III trimesters. The reduction in CD20+ B-lymphocytes is associated with bone marrow insufficiency. The findings suggest that active cytotoxic processes may contribute to the development of severe immunodeficiency in the fetus.

Key words: Rh-immunization, hemolytic disease of the fetus, T-lymphocytes CD3+, CD4+, CD8+, CD16+, CD20+ B-lymphocytes, immunoregulatory index, II, III trimester.

First page

33

Last page

37

For citation:G.U. Ashirbekova, U.U. Jabborov, Kh.M. Khatamov - INDICATORS OF INNATE CELL IMMUNITY IN HEMOLYTIC DISEASE OF THE FETAL IN PREGNANT WOMEN WITH Rh-IMMUNIZATION.//New Day in Medicine 12(74)2024 33-37 https://https://newdayworldmedicine.com/en/new_day_medicine/12-74-2024

List of References

1. de Winter DP, Kaminski A, Tjoa ML, Oepkes D: Hemolytic disease of the fetus and newborn: systematic literature review of the antenatal landscape. //BMC Pregnancy Childbirth. 2023;23:12. 10.1186/s12884-022-05329-z
2. Lakhwani S, Machado P, Pecos P, Coloma M, Rebollo S, Raya JM: Kell hemolytic disease of the fetus. Combination treatment with plasmapheresis and intrauterine blood transfusion. //Transfus Apher Sci. 2011;45:9-11. 10.1016/j.transci. 2011.06.014
3. Ghidini A: Fetal Blood Sampling. UpToDate. UpToDate, Waltham, MA; 2022.
4. Moise Jr KJ: Intrauterine fetal transfusion of red cells. UpToDate. UpToDate, Waltham, MA; 2023.
5. Zwiers C, Lindenburg IT, Klumper FJ, de Haas M, Oepkes D, Van Kamp IL: Complications of intrauterine intravascular blood transfusion: lessons learned after 1678 procedures. //Ultrasound Obstet Gynecol. 2017;50:180-6. 10.1002/uog.17319
6. Nwogu LC, Moise KJ Jr, Klein KL, Tint H, Castillo B, Bai Y: Successful management of severe red blood cell alloimmunization in pregnancy with a combination of therapeutic plasma exchange, intravenous immune globulin, and intrauterine transfusion. //Transfusion. 2018;58:677-84. 10.1111/trf.14453
7. G. Mari, M.E. Norton, J. Stone, V. Berghella, A.C. Sciscione, D. Tate, et al. Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #8: the fetus at risk for anemia–diagnosis and management. //Am J Obstet Gynecol 2015;212:697-710.
8. I.M.C. Ree, E. Lopriore, C. Zwiers, S. Böhringer, M.W.M. Janssen, D. Oepkes, et al. Suppression of compensatory erythropoiesis in hemolytic disease of the fetus and newborn due to intrauterine transfusions. //Am J Obstet Gynecol, 2020;223:119.
9. Жабборов У.У., Расуль-Заде Ю.Г., Исмаилова А.А. «Гуморальные факторы иммунитета у плода с гемолитической болезнью при резус-иммунизации», //Журнал теоретической и клинической медицины 2020;4(307):121-124.
10. Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn Hematology Am Soc Hematol Educ Program, 2015; pp.146-151.
11. M. Wind, A. Gaasbeek, L.E.M. Oosten, T.J. Rabelink, J.M.M. van Lith, M. Sueters, et al. Therapeutic plasma exchange in pregnancy: a literature review //Eur J Obstet Gynecol Reprod Biol, 2021;260:29-36.

    file

    download